This inventor holds 34 USPTO granted patents and 2 published patent applications and 2 EPO patents, primarily in Anticancer Compounds. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Company, Institute of Organic Chemistry and Biochemistry. Active years: 1990-2019.
Location History:
- Middletown, CT (US) (1990 - 2013)
- Waterford, CT (US) (2017 - 2019)
Company Filing History:
29 out of 3,735 
2 out of 637 
2 out of 50 Years Active: 1990-2019
Areas of Expertise:
Title: John E Starrett, Jr: Innovator in Anticancer Compounds
Introduction: John E Starrett, Jr., based in Middletown, Connecticut, is a prolific inventor with an impressive portfolio of 34 patents. His work primarily focuses on the development of novel compounds for therapeutic applications, particularly in the field of oncology.
Latest Patents: Among his latest innovations are two significant patents concerning 5H-pyrido[3,2-B]indole compounds as anticancer agents. This invention relates to tricyclic compounds that exhibit promising potential in treating various disorders, notably cancer. The patented formulas include pharmaceutically acceptable compositions that offer methods for effectively utilizing these compounds in therapeutic applications.
Career Highlights: John’s professional journey has seen him contribute to well-regarded organizations like Bristol-Myers Squibb Company and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences. His expertise in the field of organic chemistry has made a considerable impact on drug development processes aimed at combatting cancer.
Collaborations: Throughout his career, John E Starrett, Jr. has collaborated with notable professionals, including Piyasena Hewawasam and Muzammil M Mansuri. These partnerships have enhanced the innovation pipeline and allowed for the exchange of valuable ideas and research to create effective anticancer agents.
Conclusion: John E Starrett, Jr. exemplifies the spirit of innovation in the field of pharmacology, particularly with his advancements in anticancer compounds. His extensive patent portfolio and professional collaborations continue to contribute significantly to cancer research and treatment methodologies.